Quarterly report pursuant to Section 13 or 15(d)

COMMITMENTS AND CONTINGENCIES (Details Textual)

v3.10.0.1
COMMITMENTS AND CONTINGENCIES (Details Textual) - USD ($)
1 Months Ended 3 Months Ended
Mar. 06, 2018
May 17, 2017
Feb. 25, 2015
Jun. 30, 2018
Jun. 30, 2017
Share-based Compensation       $ 595,412 $ 251,048
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners   25.00%      
Description Of Contribution For Formation   Under the terms of the JV Contract, the JV Partner is required to contribute $290,000 within 30 days of formation, $435,000 12 months later and $725,000 60 months after the date of formation. The Company is required to contribute certain intellectual property to the China JV through a license.      
Purchase Commitment, Description On March 6, 2018, the Company signed a distribution agreement with Curexo Inc. for South Korea and as part of this agreement, the Company is obligated to buy a rehabilitative product from Curexo Inc. for $200,000 when this product is fully developed. It is not yet developed at June 30, 2018.        
Noncontrolling Interest, Ownership Percentage by Parent   75.00%      
Royalty on Sales,Percentage       1.00%  
Operating Leases, Future Minimum Payments Due, Next Twelve Months       $ 10,083  
Operating Leases, Future Minimum Payments, Due in Two Years       13,444  
Operating Leases, Future Minimum Payments, Due in Three Years       13,444  
Operating Leases, Future Minimum Payments, Due in Four Years       14,141  
Operating Leases, Future Minimum Payments, Due in Five Years       14,141  
Prepaid Deposits       18,131  
Bioniks JV Partner [Member]          
Due to Related Parties, Current       $ 93,309  
Exchangable Shares [Member]          
Stock Issued During Period, Shares, Issued for Services     262,904    
Stock Transferred To Lenders     314,560    
Stock to be Reimbursed to Officers     320,000    
Stock Issued During Period, Value, Issued for Services     $ 241,185    
Share-based Compensation     $ 210,323